This is Product is very demand due to pandamic situation. We are supplying ICMR approved ,CE certified product
We are supplier of ICMR approved ,CE certified test kits for Dengue and Malaria with international standard
3.000.000 of COVID-19 rapid tests available on stock in Romania; 1 to 2 days for delivery everywhere in Europe. We are the European representative of the Korean manufacturer of covid-19 rapid detection kit 1. GENEDIA W COVID-19 Ag, nasopharyngeal differential detection of COVID-19; 2. GENEDIA W ONE COVID-19 IgM/IgG differential detection of COVID-19 IgM and IgG; 3. GENEDIA W COVID-19 Ag (SALIVA) All the tests have CE mark, exceptional sensitivity and quality, can be used both by medical staff and for self-testing. All documentation is available upon request,
TBG SARS-CoV-2 Neutralizing Antibody Qualitative Rapid Test(colloidal gold) Now with the detection before and after vaccination, TBG''s company has a neutralizing antibody detection reagent, that it can be used as the effective rate detection of antibody before and after vaccination. No matter how the vaccine is administered, The Neutralizing Antibody Qualitative Rapid Test will be used. Our test kits for COVID-19 as below are still effective to detect the infection of new COVID-19 variant B.1.1.7and The new variant has no effect on the detection performance of products
SARS-CoV-2 IgG/IgM Rapid Test Kit Intended Use: To detect IgM and IgG antibodies against N and S protein of SARS-CoV-2 in whole blood, serum and plasma Product Format: 25 tests/kit Kit Contents: test card, diluent, capillary, lancet, and instruction for use. Storage/Stability: 2 C to 30C for 12 months.� eproducibility /Precision 100% Concordant across 3 lots with CV ±5% Performance Comparison (A) China Validation Test Positive Samples 100 / 102 Sensitivity: 98.04% Negative Samples 491/492 Specificity: 99.80% Overall Accuracy: 99.49% Performance Comparison (B) Positive Samples 23 / 25 Sensitivity: 92% Negative Samples 25 / 25 Specificity: 100% Overall Accuracy: 96%
SARS-CoV-2 Antigen Rapid Test (Nasopharyngeal swab samples) SARS-CoV-2 Antigen Rapid Test Saliva) We have two fast screening reagents for routine detection. One is the antibody iggigm detection reagent (that is, blood for three minutes) One is antigen rapid screening test reagent (the same is three minutes can use nasal mucosa, oral mucosa, and saliva three detection methods) 1.SARS-CoV-2 antigen testing can detect infection earlier than antibody testing 2.SARS-CoV-2 antigen testing can detect SARS-CoV-2 and all mutant virus strains 3.Easy operation and quick results 4.The result is clear. C-line and T-line determines the infection and the result is easy to read 5.The colloidal gold method has stable performance and is not interfered by environmental and experimental conditions 6.Application: for human throat swab , nasal swab and sputum extract Our test kits for COVID-19 as below are still effective to detect the infection of new COVID-19 variant B.1.1.7and The new variant has no effect on the detection performance of products
20 tests/box
covid antigen nasal rapid test passed the Germany PEI testing and registered on EU Common List
20 tests/box, 1 pcs/box, 5pcs/box
CareStarfTM COVID-19 ANTIGEN RAPID TESTS Why CareStartTM COVID-19 Live infection 10 minutes Diagnostic Tests dose not require a machine reader! Abbott, Quidel, and BD require readers, that are in short supply. â?¢ EASY TO USE CareStart â?¢ AVAILABILE Rapid Tests on the shelf available products (in inventory) with We offer CareStartTM reliable production and delivery schedules. Abbott, Quidel and BD testing cassettes are in short supply with unreliable availability. â?¢ FDA EUA is currently the only Point-Of-Care rapid antigen test registered authorized under the FDA EUA. CareStart TM CareStarfTM COVID-19 ANTIGEN RAPID TESTS Features Identify individual's current infection status to COVID-19 Fast and easy to use in Point-of-Care setting Qualitatively detect the SARS-CoV-2 nucleocapsid protein Use nasopharyngeal (NP) swab specimens Reliable results only in 1O minutes No special equipment or training required All-in-one package including collection swabs High sensitivity (88.4�°/o) and specificity (100�°/o) Kit Components 20 test devices 20 extraction vials and caps 20 NP swabs 1 positive and 1 negative controls Package insert Quick reference Instructions (QRI)
We can provide Covid-19 Rapid Antigen Test. Test with reliable results within minutes. Made in the USA. Lateral flow assay, No equipment required, Results within 10 minutes, minimally invasive specimen collection, nasal swab, POC (in patient care setting). Detects SARS-CoV2 nucleocapsid protein antigen with ultra high performance. Identifies acute infection with 88.4% sensitivity and 100% specificity. Complies with FDA. Principals or Buyer's Mandates only. No broker chains. FOB or CIF. Minimum order 500000 test please.
Product Description - Covid-19 SARS-CoV-2 Saliva Antigen Rapid Test Kit is an in vitro diagnostic rapid test for the qualitative detection of SARS-CoV-2 Saliva antigen (Ag) in human oropharyngeal (OP), nasal (NS), nasopharygeal (NP) swab, saliva or gargled water specimens from individuals who meet Covid-19 clinical criteria. Product origin - Turkey / Istanbul Minimum Order Size and Packaging details - 500
Product Description - SARS-CoV-2 Antigen Rapid Test Kit is an in vitro diagnostic rapid test for the qualitative detection of SARS-CoV-2 antigen (Ag) in human nasopharyngeal swab specimens from individuals who meet Covid-19 clinical criteria. Product origin - Turkey / Istanbul Key Specifications/Special Features - vitro diagnostic , Rapid Antigen Test Kit, SARS-CoV-2, Covid 19 Minimum Order Size and Packaging details - 500
SARS-CoV-2 Antigen Rapid Test Kit is an in vitro diagnostic rapid test for the qualitative detection of SARS-CoV-2 antigen (Ag) in human nasopharyngeal swab specimens from individuals who meet Covid-19 clinical criteria. Key Specifications/Special Features - vitro diagnostic , Rapid Antigen Test Kit, SARS-CoV-2, Covid 19, Nasal Rapid Test Kit
10,000 Rapid Antigen Test 500 Boxes 20 Test Per Box CE CERTIFICATION
[CONTENTS] (25) Test Kits (25) Individual Test Kits (25) Serum Pipets (1) Instruction For Use SENSITIVITY 100% | SPECIFICITY 97.3%
For in vitro qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasal (NS) swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first 5 days after onset of symptoms. This test is only provided for use by clinical laboratories or to healthcare workers for point-of-care testing, not for at-home testing. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or 2019-nCoV) is an enveloped non-segmented positive-sense RNA virus. It is the cause of coronavirus disease (COVID-19), which is contagious in humans. SARS-CoV-2 has several structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N). The antigen is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, which do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. For in vitro diagnostic use only. For professional use only .
Lateral flow assay No equipment required Rapid results within 10 minutes Minimally invasive specimen collection (nasopharyngeal swabs) POC setting (i.e. in patient care settings) by medical professionals Detects SARS-CoV-2 nucleocapsid protein antigen with ultra high performance Identify acute infection wit 88.4% sensitive and 100% specificity 20 test/box 20 test devices 20 assay buffer 20 extraction vials and caps 20 specifimen collection swabs 1 positive and 1 negative control swabs 1 instructions for use
FDA EUA
Made in Canada Health Canada approved CE Mark and ISO certified The product has proven to have 100% Specificity and 96% Sensitivety Stock availabity: 2 Million tests/kit in Canada Production: up to 5 Million tests/kit weekly The Rapid Response COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset. This test is authorized for use at the Point of Care i.e., in patient care setting. Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigen is generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patientâ??s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The Rapid Responseâ?¢ COVID-19 Antigen Rapid Test Device is for use at the Point of Care for professional use only. PRODUCT INFORMATION: Product: Rapid Respose Sample: Nasal / Nasopharyngeal secretions Format: Cassette Quantity: 25 Tests/Kit per box Time to result: 15 minutes Storage Condition: 2-30 C/36-86 F Test Principle: Immunochromatographic Assay CONTENTS - Individually packed test devices Extraction Buffer Extraction tube Nozzle with filter Tube stand Individually packed swabs Package Insert
